Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8476 to 8490 of 8973 results

  1. Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]

    Discontinued Reference number: GID-TA11163

    Technology appraisal guidance
    Discontinued

  2. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

    Highly specialised technologies guidance
    Discontinued

  3. Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]

    Discontinued Reference number: GID-TA10074

    Technology appraisal guidance
    Discontinued

  4. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued Reference number: GID-TA10234

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab for previously treated endometrial cancer [ID1205]

    Discontinued Reference number: GID-TA10243

    Technology appraisal guidance
    Discontinued

  6. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued Reference number: GID-TA10309

    Technology appraisal guidance
    Discontinued

  7. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued Reference number: GID-TA10310

    Technology appraisal guidance
    Discontinued

  8. Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]

    Discontinued Reference number: GID-TA10321

    Technology appraisal guidance
    Discontinued

  9. Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]

    Discontinued Reference number: GID-TA10327

    Technology appraisal guidance
    Discontinued

  10. Nintedanib for untreated malignant pleural mesothelioma [ID1424]

    Discontinued Reference number: GID-TA10359

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

    Discontinued Reference number: GID-TA10380

    Technology appraisal guidance
    Discontinued

  12. Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

    In development Reference number: GID-TA10483 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued Reference number: GID-TA10499

    Technology appraisal guidance
    Discontinued

  14. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued Reference number: GID-TA10527

    Technology appraisal guidance
    Discontinued

  15. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

    Discontinued Reference number: GID-TA10569

    Technology appraisal guidance
    Discontinued